OBR Daily Commentary

forumImage

A Look at Major Drug-Pricing Proposals

(New York Times) May 29, 2017 - Bills seeking to rein in the cost of prescription drugs include proposals to speed approval of generic drugs and allow the importing of cheaper drugs.

Read Article arrow

Winston Wong, PharmD (Posted: June 08, 2017)

quotesDrug importation, let Medicare negotiate rebates, PBM transparency? How long have we heard these options being bounced around. Justifying price increases is a new one, but who is going to determine what is justified and what is not. Then you have all the lobbying that goes on behind closed doors. Will anything ever be put onto the table.?quotes

Add Comment 1 Comment
forumImage

ASCO Submits Comments to FDA Commissioner on Interchangeability of Biosimilars

(ASCO in Action) May 23, 2017 - On May 19, ASCO submitted comments to Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, on the FDA’s proposed guidance for industry on demonstrating interchangeability of biosimilars with a reference product.

Read Article arrow

Winston Wong, PharmD (Posted: June 08, 2017)

quotesFully agree that the data must drive the treatment decision, however, given the growing European experience, should that be taken into account as well? For the time being, we are only looking at "similar" products today, and authorization is still required to exchange a reference product with a biosiilar.quotes

Add Comment 1 Comment
forumImage

Congressman, Pharmacist, and Lawyer Debate PBMs, Drug Prices at Annual COA Meeting

(AJMC.com) Apr 27, 2017 - At the 2017 Community Oncology Conference, participants discussed the impact of pharmacy benefit managers (PBMs) on oncology drug prices and patient access to much needed treatments.

Read Article arrow

Winston Wong, PharmD (Posted: May 08, 2017)

quotesDefinitely a very volatile topic. PBMs control a good part of the prescription claims process, but it the back room negotiations with regards to rebate's, etc that require more transparency. However, not everything can be pinned on the PBM. Bottomline is that everyone has a stake, and has contributed to the high prices.quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...